Bethesda, Md. – AABB and the International Federation for Adipose Therapeutics and Science (IFATS) announced today the launch of the 1st edition of Standards for Point of Care, Same Day Adipose Based Therapies. This joint effort focuses on same-day services for the procurement of autologous non-cultured, non-cryopreserved cells and is intended for orthopedics facilities, plastic surgery centers and academic institutions performing same-day, adipose-based therapies. Stem cells and, in particular adipose tissue-derived cells, play an important role in tissue or reconstructive medicine.
“The joint AABB/IFATS Standards for adipose-based therapies will offer a measure of quality and safety in this emerging area,” says Eduardo Nunes, MPP, CAE, AABB’s Vice President of Quality Systems, Standards and Accreditation. “Many investigators in this space are seeking support and guidance in their efforts to navigate the clinical trials process and attempt to meet FDA recommendations.”
“AABB and IFATS hope these Standards will provide a platform to help drive regulatory compliance, outcomes reporting and other necessary external evaluation activities in the adipose-based therapies space,” says IFATS Executive Committee member Dr. Adam Katz. “These recommendations will help standardize and improve patient care, providing a means to distinguish those seeking quality and regulatory compliance.”
AABB has been engaged in the development of voluntary standards in blood banking, blood component collection, processing and transfusion since 1957. Since then, AABB’s standards-setting program has moved beyond blood banking to encompass additional related disciplines and activities, including cellular therapies. Providing the basis for AABB Accreditation, AABB’s Standards seek to articulate several critical activities, including qualification for key personnel; collection, auditing and reporting of outcomes data to registries; clinical care of the patient; as well as standard operating procedures and process controls.
The 1st edition of the Standards for Point of Care, Same Day Adipose Based Therapies will be available for public comment on the AABB website through December 17, 2019.
AABB is an international, not-for-profit association representing individuals and institutions involved in the fields of transfusion medicine and cellular therapies. The association is committed to improving health through the development and delivery of standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership includes physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. AABB members are located in more than 80 countries and AABB accredits institutions in more than 50 countries.
IFATS is the premier global scientific society for adipose derived stem cell biology and applications in regenerative medicine. They draw members from around the globe, spanning disciplines of reconstructive surgery, cardiovascular biology, neurosciences, orthopedic surgery, endocrinology, developmental biology, biomaterials, bioengineering, cell therapy, stem cell biology, tissue engineering, and many others interested in regenerative medicine. Their annual international meeting features the best cutting-edge scientific work in the field of adipose stem cell research and adipose biology applied to clinical problems.
* A previous version of this press release included an incorrect statement of the scope and products covered by this first edition. AABB apologizes for this error.